Accent Microcell Ltd IPO

The Company is party to the case "Aryavart Foundation V/S Hemani industries Ltd. & Ors" for non-compliance of environmental laws.

The company may face several risks associated with the proposed expansion of its manufacturing of CCS at the Proposed Unit, which could hamper its growth, prospects, cash flows and business and financial condition.

There may be potential conflict of interests between the Company and its Group Entities.

The company relies on a limited number of suppliers for sourcing its raw materials. Furthermore, the company has not entered into any longterm agreement or contract of supply of raw materials and consequently are exposed to price and supply fluctuations for its raw materials.

The company derives a significant portion of its revenue from the sale of certain products and any reduction in demand for these products could have an adverse effect on its business, results of operations and financial condition.

Its Major Exports are to Brazil, United Kingdom, United States, Russia, Republic of Korea, Turkey, Germany, Bangladesh, Egypt, Netherland, Indonesia.

Substantial portion of its revenues has been dependent upon the company few clients (Top 10). The loss of any one or more of its major clients would have a material effect on the company business operations and profitability.

Its revenues are dependent on clients concentrated in the pharmaceutical industry for a significant portion of its revenue. An economic slowdown or factors affecting this segment may have an adverse effect on its business, financial condition and results of operations.

The company depends on its promoters, directors, key managerial personnel and senior management and its heavily relies on their knowledge and experience in operating its business and therefore, it is critical for the company's business that they remain associated with it.

The Company has in the past entered into related party transactions and may continue to do so in the future. There can be no assurance that such transactions, individually or in the aggregate, will not have an adverse effect on the Company's financial condition and results of operations.